Skip to content

Study · Animal study (in vivo) · mouse · 1999

4 results

Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids.

Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ, Stevenson RD

Nature medicine1 Dec 1999Cited by 143 (Europe PMC)

PMID10581087 (opens in a new tab)DOI10.1038/71002 (opens in a new tab)PepBankPUB-10581087
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, oxidized thymosin beta4 was a potent inhibitor of carrageenin-induced paw edema, unlike the native form.

    In plain wordsIn mice, the oxidized form of thymosin beta4 strongly reduced paw swelling, which the native form did not do.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseCarrageenin-induced paw edema, oxidized peptide
    Study

    mousen: not reported in source

    carrageenin-induced paw edema
    Comparator
    Native thymosin beta4
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    in vivo, the oxidized peptide, but not the native form, was a potent inhibitor of carrageenin-induced edema in the mouse paw.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, native thymosin beta4 did not inhibit carrageenin-induced paw edema.

    In plain wordsIn mice, the native form of thymosin beta4 did not reduce paw swelling.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeCarrageenin-induced paw edema, native peptide
    Study

    mousen: not reported in source

    carrageenin-induced paw edema
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    in vivo, the oxidized peptide, but not the native form, was a potent inhibitor of carrageenin-induced edema in the mouse paw.
  3. 03LabIn vitro (cells)Activity measurement

    In vitro, thymosin beta4 sulfoxide inhibited neutrophil chemotaxis.

    In plain wordsIn lab tests, the oxidized form of thymosin beta4 reduced the movement of neutrophils, a type of immune cell.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseNeutrophil chemotaxis in vitro
    Study

    n: not reported in source

    neutrophil chemotaxis assay
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, thymosin beta4 sulfoxide inhibited neutrophil chemotaxis

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 04LabEndogenous levelIn vitro (cells)Mechanism

    Monocytes generated thymosin beta4 sulfoxide in the presence of glucocorticoids.

    In plain wordsIn cells, monocytes made the body's own oxidized thymosin beta4 when glucocorticoids were present.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseThymosin beta4 sulfoxide generation by monocytes with glucocorticoids
    Study

    n: not reported in source

    monocytes cultured with glucocorticoids
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    thymosin beta4 sulfoxide is generated by monocytes in the presence of glucocorticoids

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.